The Cell Therapy Scale-Out
Across 1 sector, 2 filers are signaling rising demand. Visible since 2025Q2, with activity continuing through 2026Q1. Almost entirely a demand story (100%). One disclosure notes "Net revenues for Vyalev increased greater than 100% for the three months ended March 31, 2026." Continuing to gain pace.
Leading pharmaceutical companies are expanding treatment capacity and sites while capturing share in high-growth specialty therapies, converting manufacturing and distribution constraints into a growth lever.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Language shifts from constrained supply as a bottleneck to capacity expansion as an active competitive strategy for share capture.
REPRESENTATIVE SIGNAL FROM FILINGS
“Net revenues for Vyalev increased greater than 100% for the three months ended March 31, 2026”
Vyalev net revenues grew more than 100% in the three months ended March 31, 2026, driven by strong market share gains.
“Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion”
CARVYKTI sales increased due to share gains and capacity expansion.
DRIVERS